What Syngoi Technologies does

Syngoi Technologies S.L. is a Spanish biotechnology CDMO founded in 2021 by Columbus Venture Partners in Zamudio (Bizkaia), Spain, focused on manufacturing optimized linear synthetic DNA (oDNA) for advanced cell and gene therapies. The company operates a proprietary cell-free enzymatic cGMP platform that produces double-stranded closed linear DNA customized through a library of natural and non-natural nucleotide adaptors, allowing modulation of DNA properties such as stability, immunogenicity, vector release, and nuclear translocation. Service offerings span feasibility, preclinical, clinical-GMP manufacturing, sterile fill & finish, and dedicated project management supported by SAP HANA-based traceability; current facility footprint is 2,500 m² with four cGMP suites, expandable to 4,000 m² and 12 suites.

The business serves biotech and pharmaceutical companies developing mRNA and DNA vaccines, CAR-T cell therapies, gene-editing programs, and viral and non-viral gene therapies, with roughly 90% of customers located in Europe and the United States and capacity for over 25 concurrent projects at kilograms scale post-Series B. Syngoi monetizes via project-based, quote-driven CDMO contracts ranging from R&D/preclinical work through commercial launch support. Active R&D programs include SYNODNA (modular DNA structures), ADNOVA (DNA for AAV manufacturing), and SYNENZYM (engineered Phi29 polymerase), several co-funded by the Basque Government and FEDER. In January 2026 Syngoi was acquired by U.S.-based Artis BioSolutions, retaining its Bilbao industrial base while extending the enzymatic platform to Boston via Artis's Landmark Bio facility in March 2026. Syngoi holds granted patents on its cell-free DNA production method and on oDNA constructs.

Name

Syngoi Technologies

Legal name

SYNGOI TECHNOLOGIES S.L.

Website

https://syngoi.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

11–50 employees

Short description

Syngoi Technologies is a Spanish biotech CDMO founded in 2021 that manufactures proprietary cell-free enzymatic synthetic DNA (oDNA) under cGMP for biotech and pharma developing gene therapies, mRNA vaccines, and cell therapies.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

akta.pro secondary industries

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

Keywords

• Synthetic DNA manufacturing
• Cell and gene therapy
• CDMO services
• MRNA vaccine production
• Enzymatic DNA synthesis

Headquarters

HQ city

Zamudio

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. CDMO Manufacturing Services: Contract Development and Manufacturing Organization providing synthetic DNA production services to biotech and pharmaceutical companies. Services span from R&D and preclinical stages through clinical GMP manufacturing and commercial launch support.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Syngoi Technologies is a Contract Development and Manufacturing Organization (CDMO) that produces optimized linear synthetic DNA (oDNA) using a proprietary cell-free enzymatic cGMP process. The company supplies biotech and pharmaceutical clients with high-purity synthetic double-stranded linear closed DNA customized through proprietary adaptor sequences, supporting applications including mRNA vaccines, CAR-T cell therapy, gene editing, and viral and non-viral gene therapies. Services span R&D and preclinical stages through clinical GMP manufacturing and commercial launch support.

Product overview

Syngoi Technologies is a CDMO (Contract Development and Manufacturing Organization) specializing in synthetic DNA manufacturing for advanced cell and gene therapies. The company's core offering is its proprietary Optimized Linear Synthetic DNA (oDNA) product, a cell-free enzymatic cGMP-manufactured synthetic DNA platform. The technology portfolio includes closed linear DNA, open linear double-stranded, and open linear single-stranded DNA formats, each customized with Syngoi's proprietary adaptor library to optimize properties such as stability, immunogenic response, release from delivery vectors, and nuclear translocation. Adjacent offerings include R&D projects (SYNODNA, ADNOVA, SYNENZYM) for novel DNA structures and enzyme engineering, full cGMP manufacturing services with sterile fill & finish capabilities, HPLC analytical method development, and dedicated project management support.

Differentiator

Problem solved

Functional benefit

Products and services

• Optimized Linear Synthetic DNA (oDNA)

Quantifiable outcome

• DNA production in weeks instead of months (compared to traditional pDNA production)
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Artis BioSolutionscoreStrategic or Co-development Partner · 14 January 2026Artis BioSolutions (San Diego-based advanced therapies company) completed acquisition of Syngoi Technologies from Columbus Venture Partners and Buenavista Equity Partners in January 2026. Syngoi maintains and expands its scientific and industrial base in Bilbao, Spain while Artis establishes U.S. presence through its Landmark Bio facility in Watertown, MA using Syngoi's enzymatic DNA platform.
• Ribbon BiocoreStrategic or Co-development Partner · 10 March 2025Strategic collaboration to advance gene therapies through development and manufacture at gram scale of clinically and commercially ready synthetic DNA. Combines Syngoi's manufacturing capabilities with Ribbon Bio's algorithm-driven DNA synthesis technology to produce pristine synthetic DNA molecules for next-generation gene therapies.
• Afrigen / CEPIminorStrategic or Co-development Partner · 9 September 2024CEPI funded project ($2.05 million) with Afrigen exploring synthetic DNA as an alternative to traditional plasmid DNA for accelerating mRNA vaccine development, potentially reducing development times by up to 3 times. Syngoi's technology enables 10-day production of synthetic DNA.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Touchlight Genetics: U.K.-based synthetic DNA manufacturer using an enzymatic, cell-free approach to produce doggybone DNA (dbDNA) for gene therapy and DNA vaccines — the most direct technology competitor to Syngoi's enzymatic oDNA platform, serving overlapping advanced-therapy customers.
• Genezen: U.S.-based viral vector and gene therapy CDMO offering GMP-grade lentiviral, AAV, and cell processing services; comparable as a focused advanced-therapy CDMO serving similar biotech and pharma customers, though specialized in vectors rather than DNA.
• VGXI (Genezen/pregenex): U.S.-based contract manufacturer specializing in plasmid DNA for gene therapy, DNA vaccines, and cell therapy applications; direct competitor in GMP-grade DNA supply with established customer base.

Broad incumbents

• Aldevron: U.S.-based (now part of Danaher) CDMO and the dominant plasmid DNA supplier for gene therapy and vaccine developers globally; competes with Syngoi on starting-material supply though using bacterial fermentation rather than enzymatic production.
• Charles River Laboratories: Large global CRO/CDMO offering plasmid DNA, viral vector, and cell therapy manufacturing services; competes with Syngoi in the cell and gene therapy CDMO segment with broader portfolio scale.
• Catalent: Global CDMO with biologics, cell therapy, and gene therapy manufacturing services (now part of Novo Holdings); competes with Syngoi for advanced-therapy manufacturing engagements, particularly around viral vector and cell therapy supply chains.
• AGC Biologics: Global CDMO offering cell and gene therapy, viral vector, and biopharmaceutical manufacturing services; overlaps with Syngoi in serving gene therapy developers requiring GMP-grade DNA and vector supply.
• Cobra Biologics (Charles River): U.K./Sweden-based plasmid DNA, viral vector, and cell therapy CDMO (now part of Charles River); competes with Syngoi in plasmid DNA and gene therapy manufacturing services for European biotech customers.

Emerging players

• DNA Script: French/U.S. enzymatic DNA synthesis technology company developing enzymatic oligonucleotide synthesis; an emerging alternative DNA-writing technology with potential overlap to Syngoi's enzymatic approach for therapeutic DNA applications.
• Twist Bioscience: U.S.-based DNA synthesis company providing synthetic DNA, including clonal genes and DNA fragments, with growing capabilities in DNA data storage and biologic discovery; competes in synthetic DNA supply with a silicon-based platform, partially overlapping Syngoi's customer base.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/syngoi-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syngoi Technologies